- Serum baseline tryptase (sBT) distinguished children with asthma from healthy controls, except in cases of mild intermittent asthma.
Why this matters
- sBT level may have potential as a predictor of disease severity.
- Median sBT levels in mild and moderate-severe persistent asthma were 4.2 μg/L and 4.7 μg/L, respectively.
- Levels were similar in mild intermittent asthma vs healthy controls ( 3.1 vs 2.5 μg/L; P=.335).
- To distinguish children with asthma vs healthy controls, a cut-off of 3.2 μg/L showed sensitivity of 75.4%, specificity of 88.2%, and AUC of 0.844.
- To distinguish persistent vs intermittent asthma, a cut-off value of 3.6 μg/L had 85.9% sensitivity, 88.9% specificity, and AUC of 0.906.
- sBT showed weak performance in distinguishing patients with mild intermittent asthma vs healthy controls (sensitivity 41.7%, specificity 88.2%, AUC 0.646).
- sBT strongly correlated with childhood asthma control test (C-ACT) scores, serum IgE, and eosinophil counts.
- sBT did not significantly corelate with C-ACT scores in mild intermittent asthma.
- sBT was closely associated with FEV1 predicted, FEV1:FVC, serum interleukin-13 (IL-13) levels, and interferon-gamma (IFN-γ):IL-13, but not serum IFN-γ levels.
- Observational study of 114 children with asthma and 34 age-matched controls.
- Funding: None.
- Small, monocentric, monoethnic study.